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High rates of pneumococcal diseases occur despite the availability of 23-valent
pneumococcal polysaccharide vaccine (PPV23) in the elderly aged above 65 in Tai-
wan. A 13-valent pneumococcal conjugate vaccine (PCV13) is developed for use in
high-risk adults. OBJECTIVES: To examine the health and economic impact of
PCV13 compared with PPV23 in Taiwan.METHODS: An age-stratified (18-49, 50-64,
65-74, 75-84, 85-99) micro-simulation Markovmodel was developed and populated
with local data inputs to simulate the potential public health and economic out-
comes of PCV13 versus PCV23 against invasive pneumococcal diseases (meningitis
and bacteremia) and all-cause pneumonia when used as routine vaccination of
infants in Taiwanover a life-timehorizon. Costs include directmedical cost such as
hospitalization, medical outpatient visits, medications and indirect cost. Both ep-
idemiological and cost data inputs were derived retrospectively from National
Health Insurance Reimbursement Database and public sources where available.
The study was performed from both payer and societal perspectives using 3%
discount rate for both costs and life years. Sensitivity analyses were conducted to
test the robustness of model outcomes. RESULTS: Model projected that PCV13
vaccination compared with PPV23 can prevent 96, 4,549, 1,110,253 and 1,548,947
cases of meningitis, bacteremia, outpatient pneumonia, and inpatient pneumonia
respectively while saving 167,065 deaths, equivalent to 201,166 life years. PCV13
vaccination is estimated to save an direct (indirect) cost of NTD113,952M
(NTD17,182M) over 82 years. Given market price assumption of one dose of PCV13
and PPV23 (NTD3,000 vs. NTD700), PCV13 vaccination on adults is expected to lead
to NTD57,334 (NTD36,476) per life year saved in 50-64 age group and is cost-saving
for all elder age groups from both payer (societal) perspective compared to PPV23.
CONCLUSIONS: PCV13 adult vaccination in Taiwan was estimated to reduce the
burden of pneumococcal diseases and expected to be cost-effective from both
payer and societal perspectives.
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OBJECTIVES: To examine the cost-effectiveness of adding nucleic acid testing
(NAT) to enzyme immunoassay (EIA) screening for hepatitis B (HBV), hepatitis C
(HCV), and human immunodeficiency virus (HIV) in Taiwan based on the govern-
mental perspective. METHODS: A Markov model depicting the natural history of
HBV, HCV, and HIV infections and subsequent illnesses for blood recipients in
Taiwan was developed to evaluate the cost-effectiveness of adding five different
NAT screening strategies employing different test systems and pool sizes to EIA
screening, including cobas TaqScreen multiplex in pools of 6 (EIACobas6), Proce-
lix Ultrio in individual donations (EIAUltrio1), or pools of 4 (EIAUltrio4), and
Procelix Ultrio Plus in individual donations (EIAUPlus1), or pools of 8
(EIAUPlus8). The population size and characteristics of the recipients were de-
rived from the National Health Insurance (NHI) data. Transition probabilities and
utilities were abstracted from published literature. Efficacy and screening costs
were obtained from a nationwide NAT screening program launched in Taiwan.
Medical costs incurred by infections and subsequent illnesses were obtained from
the NHI and published literature based on Taiwanese data. Both costs and health
outcomes were discounted at 3%. All costs were presented in 2012 USD. Probabi-
listic sensitivity analyses were performed. RESULTS: A 270,535-recipient cohort
based on the annual number of recipients in Taiwan, was simulated. The model
predicted that for variousNAT screening strategies 120-400 infectionswere averted
with additional 6.8-13.6 million NAT screening costs, corresponding to 34,200-
72,400 USD per infection averted, and the lifetime incremental costs per quality-
adjusted life-year (QALY) gained were 48,600-72,400 USD/QALY. Wide variation,
however, was seen and the probability that NAT being cost-effective was 18-30%.
CONCLUSIONS: EIACobas6 and EIAUPlus8 are the two strategies of better cost-
effectiveness. At the threshold of three-fold GDP per capita (55,800 USD/QALY),
EIACobas6 and EIAUPlus8 may be considered as cost-effective in Taiwan but
with high uncertainty.
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OBJECTIVES: To investigate the cost effectiveness of Hyperbaric oxygen therapy (HBOT)
for the treatment of non-neurological soft tissue radiation injuries.METHODS: The eco-
nomic evaluation adopted a decision analytic framework comparingHBOT to usual
care for the treatment of non-neurological soft tissue radiation injuries. The incre-
mental costs per patient wound healed/improved were presented. Estimates of
effectivenesswere obtained from a published RCT (Clarke et al, 2008). Resource use
was determined from HIC data (Medicare and Pharmaceutical Benefits Schemes),
the Australian Department of Health and Ageing and expert opinion. RESULTS: For
the base case analysis, significant/moderate improvement or complete wound
healing was demonstrated in 88.9 per cent of patients who received HBOT for soft
tissue radiation injuries, and the comparable figure for usual care was 62.5 per cent
of patients. Therefore providing HBOTwould result in an additional 26.4 per cent of
patients being successfully treated. The average cost accrued in the HBOT-treated
group was $11,753 per patient compared to $12,482 in the usual care group. This
represents a cost savings of $728 per patient, meaning that HBOT dominates usual
care (i.e. HBOT is less expensive and is more effective). CONCLUSIONS: The results
indicate that HBOT is a cost-effective alternative to usual care for the treatment of
soft tissue radiation injuries. There is considerable uncertainty around the esti-
mates of usual care due to the complexity of the treatment pathway.
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OBJECTIVES: To evaluate the cost-effectiveness of high-dose dabigatran (150 mg
twice daily) against genotype-guided warfarin dosing in nonvalvular atrial fibrilla-
tion (AF) patients requiring anticoagulation for stroke prevention from the US pay-
er’s perspective. Conventional dose-adjusted warfarin has been the main antico-
agulation strategy for decades. Newer treatment strategies such as oral direct
thrombin inhibitor dabigatran and genotype-guided warfarin dosing offer several
advantages over warfarin. To the best of our knowledge, there is no head-to-head
study evaluating the cost-effectiveness of dabigatran and genotype-guided warfa-
rin dosing versus conventional warfarin.METHODS:AMarkov decisionmodel was
constructed to derive the incremental cost effectiveness ratios (ICERs; in US$ per
QALY) of dabigatran and genotype-guided warfarin dosing versus conventional
warfarin in a hypothetical cohort of 70-year-old patients with newly-diagnosed AF
and moderate stroke risk (CHADS2 score1). The time horizon is 20 years. Costs,
utilities and adverse event rates were derived from published studies. One-way
and two-way sensitivity analyses were performed. RESULTS: At an ICER of
US$17,260 per QALY, high-dose dabigatran provided an additional 0.30 QALYs over
genotype-guidedwarfarin dosing in the base-case. Themodelwas only sensitive to
drug costs. Among patients with amoderate to high intracranial hemorrhage (ICH)
risk, at the current retail price of US$8 a day, high-dose dabigatran was the most
cost-effective option for all stroke risk groups. Conventional warfarin dosing re-
mains most cost-effective for patients with a low ICH risk. CONCLUSIONS: In 70-
year-old patients with nonvalvular AF andmoderate stroke risk (CHADS2 score1),
high-dose dabigatran was cost-effective compared to genotype-guided warfarin
dosing, at National Institute for Health and Clinical Excellence’swillingness-to-pay
thresholds of US$30,000 to US$45,000 (£20,000 to £30,000) per QALY gained. By
using a common Markov model to compare three treatments, we overcome the
limitations of the conventional league table approach (limited comparability due to
differences in models used across studies).
PODIUM SESSION I:
CANCER OUTCOMES STUDIES
CN1
STATINS AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS
WITH HEPATITIS B VIRUS INFECTION
V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 – A 6 8 1
Avai lable onl ine at www.sc iencedirect .com
journal homepage: www.elsevier .com/ locate / jva l
Copyright © 2012, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
